The Nigerian Investor
← All researchMay & Baker Nigeria Plc (MAYBAKER) · Pharmaceuticals · 9M 2026

May & Baker 9M 2026: A 10-Point Margin Leap, Net Cash and a Single-Digit P/E

The verdict

May & Baker delivered the cleanest result in listed pharma. Revenue rose only 4.9%, but gross margin jumped to about 44.3% from 34.2% and operating profit rose 66%. Interest income (N861.9m) now exceeds finance costs (N368.5m), group net cash is about N3.91bn, and at N39.20 the stock trades on about 9.7x trailing earnings even after more than doubling in a year. The risks are whether the margin can last and an inventory build funded by suppliers. The sector's best quality-to-price ratio, provided gross margin holds above about 40%.

Key numbers (Group, N'000)

Item

9M 2026

9M 2025

Change

Revenue

30,967,740

29,525,378

+4.9%

Gross profit

13,709,716

10,112,321

+35.6%

Gross margin

44.3%

34.2%

+10.1ppt

Operating profit

8,448,833

5,078,891

+66.4%

Interest income

861,929

412,840

+109%

Finance costs

368,465

541,651

−32%

PBT

8,922,253

4,915,135

+81.5%

Tax (ETR ~34%)

3,033,566

1,572,843

+92.9%

PAT

5,888,687

3,342,292

+76.2%

EPS (kobo)

341.33

193.73

+76%

Q3 revenue / PAT

11,687,373 / 2,688,809

10,241,847 / 1,156,684

+14.1% / +132%

Source: May & Baker 9M 2026 unaudited group filing (NGX). Percentages are TNI Research calculations.

What drove the results

The margin jump came from cost of sales falling 11% while revenue rose about 5%. That points to lower input costs in naira terms (a stable naira and the raw-material duty waiver) combined with price increases taken earlier. Q3 gross margin reached about 51.6% against 33.6% a year earlier. Some of this likely reflects inventory bought at better exchange rates, which unwinds as stock turns over, so a 40–44% gross margin is a more realistic run-rate than Q3's 51.6%.

Other drivers: operating costs stayed disciplined (distribution +2%, admin +5%). Regional sales: Lagos N10.92bn, East N10.02bn, West N6.84bn, North N3.73bn. The Biovaccines joint-venture loss narrowed to N20.0m.

Forensic flags

  1. Inventory doubled, funded by suppliers. Inventories rose to N9.71bn from N4.73bn, with raw materials more than tripling to N3.49bn. Trade creditors rose to N6.66bn from N1.29bn. That is about 154 inventory days and 105 payable days. If suppliers tighten terms, about N5.4bn of working capital must be funded.

  2. Earnings quality slightly below 1x. Operating cash flow of N5.25bn is about 0.89x PAT, because receivables also rose to N4.04bn from N2.37bn.

  3. Segment reconciliation gap. Segment revenue (N31.50bn) does not reconcile to reported revenue (N30.97bn). The N536m difference is likely inter-segment eliminations, but it is not disclosed.

  4. Concessional debt repricing. The BOI N850m loan rate rose to 15% from 9% from 1 June 2026.

  5. Tax-law prior-period adjustment. A N141.8m adjustment is attributed to the Nigeria Tax Administration Act 2025. Ask for the detail at FY.

  6. Restricted cash. About N645.5m of the N7.16bn cash is unclaimed dividends. Excluding it, net cash is about N3.26bn.

Valuation (TNI Research calculations)

  • N39.20 × 1,725,234,886 shares: market cap about N67.6bn.

  • TTM PAT about N6.98bn; TTM EPS about N4.05; P/E about 9.7x.

  • P/B about 3.6x; annualised ROE about 42%.

  • FY2025 dividend N0.50, a yield of about 1.3%. The payout of about 19% leaves room to raise the FY2026 dividend.

  • Free float of 35.16%, the most liquid in this group.

What to watch

  • Q4 gross margin: above 40% confirms the thesis.

  • Inventory and payables unwinding.

  • FY2026 dividend size.

  • Further BOI rate resets.

  • Beverage segment economics.

Sources

Source: May & Baker 9M 2026 unaudited NGX filing. This is analysis for education, not investment advice.

TNI Research publishes independent analysis for education. It is not investment advice. Do your own research or consult a licensed adviser before investing.